MedPath

CHUGAI PHARMACEUTICAL CO., LTD.

CHUGAI PHARMACEUTICAL CO., LTD. logo
🇯🇵Japan
Ownership
Public, Subsidiary
Established
1925-03-10
Employees
7.6K
Market Cap
$83.6B
Website
http://www.chugai-pharm.co.jp
Clinical Trials
Related News

A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Chronic Hepatitis C (CHC) Patients With Compensated Liver Cirrhosis (LC)

Phase 3
Completed
Conditions
Liver Cirrhosis
Chronic Hepatitis C
Interventions
Drug: peginterferon alfa-2a 180μg
Drug: peginterferon alfa-2a 90μg
First Posted Date
2006-03-20
Last Posted Date
2010-06-03
Lead Sponsor
Chugai Pharmaceutical
Target Recruit Count
180
Registration Number
NCT00304551
Locations
🇯🇵

Tohoku Region, Tohoku, Japan

🇯🇵

Hokkaido Region, Hokkaido, Japan

🇯🇵

Kyusyu Region, Kyusyu, Japan

and more 5 locations

Trial of Pegasys® in Patients With Chronic Hepatitis C

Phase 4
Completed
Conditions
Chronic Hepatitis C
Interventions
First Posted Date
2005-10-28
Last Posted Date
2010-11-17
Lead Sponsor
Chugai Pharmaceutical
Target Recruit Count
108
Registration Number
NCT00245414
Locations
🇯🇵

Hokkaido Region, Sapporo, Japan

🇯🇵

Chugoku Region, Okayama, Japan

🇯🇵

Kinki Region, Osaka, Japan

and more 3 locations

Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA220JP or MRA221JP

Phase 3
Completed
Conditions
Rheumatoid Arthritis
Interventions
Drug: MRA(Tocilizumab)
First Posted Date
2005-09-05
Last Posted Date
2013-08-09
Lead Sponsor
Chugai Pharmaceutical
Target Recruit Count
42
Registration Number
NCT00144586

A New Active Vitamin D, ED-71 for Osteoporosis

Phase 3
Completed
Conditions
Osteoporosis
Interventions
Drug: ED-71 placebo
First Posted Date
2005-09-05
Last Posted Date
2013-08-09
Lead Sponsor
Chugai Pharmaceutical
Target Recruit Count
1056
Registration Number
NCT00144456

Study of MRA in Patients With Rheumatoid Arthritis (RA)

Phase 2
Completed
Conditions
Rheumatoid Arthritis
Interventions
Drug: MRA(Tocilizumab)
First Posted Date
2005-09-05
Last Posted Date
2013-08-09
Lead Sponsor
Chugai Pharmaceutical
Target Recruit Count
135
Registration Number
NCT00144651

Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA012JP

Phase 3
Completed
Conditions
Rheumatoid Arthritis
Interventions
Drug: MRA(Tocilizumab)
First Posted Date
2005-09-05
Last Posted Date
2013-08-09
Lead Sponsor
Chugai Pharmaceutical
Target Recruit Count
241
Registration Number
NCT00144547

A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy

Phase 3
Completed
Conditions
Chemotherapy Induced Anemia
Interventions
First Posted Date
2005-09-05
Last Posted Date
2009-02-02
Lead Sponsor
Chugai Pharmaceutical
Target Recruit Count
122
Registration Number
NCT00144482

A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Patients With Chronic Hepatitis C

Phase 3
Completed
Conditions
Chronic Hepatitis C
First Posted Date
2005-09-05
Last Posted Date
2009-02-02
Lead Sponsor
Chugai Pharmaceutical
Target Recruit Count
300
Registration Number
NCT00144469

Phase III Comparative Study(Open-Label) of MRA for Rheumatoid Arthritis(RA)

Phase 3
Completed
Conditions
Rheumatoid Arthritis
Interventions
Drug: MRA (Tocilizumab)
Other: current treatment
First Posted Date
2005-09-05
Last Posted Date
2009-02-02
Lead Sponsor
Chugai Pharmaceutical
Target Recruit Count
306
Registration Number
NCT00144508

Comparative Study (Double-Blind) of MRA for Rheumatoid Arthritis (RA)

Phase 3
Completed
Conditions
Rheumatoid Arthritis
Interventions
Drug: MRA(Tocilizumab)
Drug: MRA placebo
First Posted Date
2005-09-05
Last Posted Date
2009-02-02
Lead Sponsor
Chugai Pharmaceutical
Target Recruit Count
127
Registration Number
NCT00144521
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy